ASBP Stock Analysis: Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a mel
- Latest close
- $8.78
- 20-day change
- +0.00%
- Trend state
- NEUTRAL
- Classification
- Healthcare · Biotechnology
Market context
Aspire Biopharma Holdings, Inc. moved +0.00% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.
Latest report
The latest cached company filing period (FY2025 · $6.2K revenue · -$24.5M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Future is currently the strongest dimension at 2.3/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.